NAAA
CPRX

New Age Alpha Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

New Age Alpha Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$153K Sell
4,867
-207
-4% -$6.11K 0.01% 797
2026
Q1 		$126K Sell
5,074
-124
-2% -$2.95K 0.01% 666
2025
Q4 		$121K Buy
+5,198
New +$116K 0.01% 668

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

New Age Alpha Advisors's CPRX Position: Q2 2026 in Review

New Age Alpha Advisors reduced its Catalyst Pharmaceutical (CPRX) stake by 4.1% in Q2 2026, selling an estimated $6.11K and leaving 4,867 shares worth $153K. The position accounts for 0.01% of the portfolio, ranked #797.

New Age Alpha Advisors first reported a position in CPRX in Q4 2025 and has held it in 3 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • New Age Alpha Advisors held 4,867 shares of Catalyst Pharmaceutical worth $153K as of Q2 2026.
  • New Age Alpha Advisors sold 207 Catalyst Pharmaceutical shares in Q2 2026, an estimated $6.11K.
  • Catalyst Pharmaceutical made up 0.01% of New Age Alpha Advisors's portfolio in Q2 2026, its #797 holding.
  • New Age Alpha Advisors first reported a position in Catalyst Pharmaceutical in Q4 2025 and has held it in 3 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on New Age Alpha Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.